RedHill Biopharma Ltd. (RDHL)
USD 2.43
(-12.77%)
USD 2.43
(-12.77%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.18 Million USD | -105.05% |
| 2022 | 102.72 Million USD | 76.08% |
| 2021 | 58.33 Million USD | 1.27% |
| 2020 | 57.6 Million USD | 328.53% |
| 2019 | -25.2 Million USD | 13.09% |
| 2018 | -29 Million USD | -76.27% |
| 2017 | -16.45 Million USD | 69.41% |
| 2016 | -53.78 Million USD | -149.98% |
| 2015 | -21.51 Million USD | -265.17% |
| 2014 | -5.89 Million USD | 50.28% |
| 2013 | -11.85 Million USD | 29.52% |
| 2012 | -16.81 Million USD | -19.5% |
| 2011 | -14.07 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | -5.18 Million USD | -105.05% |
| 2023 Q2 | -4.71 Million USD | 55.45% |
| 2023 Q1 | -10.57 Million USD | -110.3% |
| 2022 Q1 | 66.16 Million USD | 13.41% |
| 2022 FY | 102.72 Million USD | 76.08% |
| 2022 Q4 | 102.72 Million USD | -2.75% |
| 2022 Q3 | 105.62 Million USD | 58.46% |
| 2022 Q2 | 66.65 Million USD | 0.75% |
| 2021 Q1 | 11.57 Million USD | -79.9% |
| 2021 Q4 | 58.33 Million USD | -10.05% |
| 2021 Q3 | 64.85 Million USD | 80.09% |
| 2021 FY | 58.33 Million USD | 1.27% |
| 2021 Q2 | 36.01 Million USD | 211.0% |
| 2020 Q3 | 59.69 Million USD | -4.23% |
| 2020 Q4 | 57.6 Million USD | -3.49% |
| 2020 Q1 | 1.62 Million USD | 106.43% |
| 2020 FY | 57.6 Million USD | 328.53% |
| 2020 Q2 | 62.33 Million USD | 3742.79% |
| 2019 Q2 | -4.92 Million USD | 75.31% |
| 2019 Q3 | -7.68 Million USD | -56.06% |
| 2019 Q4 | -25.2 Million USD | -227.97% |
| 2019 FY | -25.2 Million USD | 13.09% |
| 2019 Q1 | -19.94 Million USD | 31.23% |
| 2018 FY | -29 Million USD | -76.27% |
| 2018 Q4 | -29 Million USD | -55.24% |
| 2018 Q3 | -18.68 Million USD | -235.8% |
| 2018 Q2 | -5.56 Million USD | 26.4% |
| 2018 Q1 | -7.56 Million USD | 54.06% |
| 2017 Q1 | -29.62 Million USD | 44.92% |
| 2017 FY | -16.45 Million USD | 69.41% |
| 2017 Q4 | -16.45 Million USD | 11.83% |
| 2017 Q3 | -18.66 Million USD | -21.83% |
| 2017 Q2 | -15.31 Million USD | 48.29% |
| 2016 Q1 | -12.02 Million USD | 44.11% |
| 2016 FY | -53.78 Million USD | -149.98% |
| 2016 Q4 | -53.78 Million USD | -694.24% |
| 2016 Q3 | -6.77 Million USD | -97.78% |
| 2016 Q2 | -3.42 Million USD | 71.53% |
| 2015 FY | -21.51 Million USD | -265.17% |
| 2015 Q4 | -21.51 Million USD | 54.78% |
| 2015 Q3 | -47.58 Million USD | -539.64% |
| 2015 Q2 | -7.43 Million USD | 12.21% |
| 2015 Q1 | -8.47 Million USD | -43.82% |
| 2014 Q1 | -37.41 Million USD | -215.7% |
| 2014 FY | -5.89 Million USD | 50.28% |
| 2014 Q4 | -5.89 Million USD | 50.93% |
| 2014 Q3 | -12 Million USD | 29.96% |
| 2014 Q2 | -17.14 Million USD | 54.17% |
| 2013 Q4 | -11.85 Million USD | 9.98% |
| 2013 FY | -11.85 Million USD | 29.52% |
| 2013 Q2 | -14.17 Million USD | 9.87% |
| 2013 Q1 | -15.72 Million USD | 6.45% |
| 2013 Q3 | -13.16 Million USD | 7.13% |
| 2012 FY | -16.81 Million USD | -19.5% |
| 2012 Q3 | -9.57 Million USD | 0.0% |
| 2012 Q4 | -16.81 Million USD | -75.64% |
| 2011 Q4 | -14.07 Million USD | 0.0% |
| 2011 FY | -14.07 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 381.586% |
| Alpha Teknova, Inc. | 1.97 Million USD | 362.717% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 105.505% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 106.919% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 101.191% |
| Cosmos Health Inc. | 8.59 Million USD | 160.368% |
| Journey Medical Corporation | -9.7 Million USD | 46.585% |
| Embecta Corp. | 1.31 Billion USD | 100.395% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.131% |
| Dynavax Technologies Corporation | 106.63 Million USD | 104.863% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 96.036% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 101.198% |
| PainReform Ltd. | -7.95 Million USD | 34.767% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 66.83% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 66.83% |
| SCYNEXIS, Inc. | -19.35 Million USD | 73.199% |
| Safety Shot Inc | -2.28 Million USD | -127.022% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 45.003% |
| Procaps Group, S.A. | 242.93 Million USD | 102.135% |
| Theratechnologies Inc. | 24.87 Million USD | 120.852% |
| Harrow Health, Inc. | 116.41 Million USD | 104.455% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -105.795% |
| Biofrontera Inc. | 4.05 Million USD | 227.861% |
| DURECT Corporation | -7.65 Million USD | 32.244% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 84.532% |
| Cronos Group Inc. | -663.32 Million USD | 99.218% |
| OptiNose, Inc. | 58.06 Million USD | 108.931% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 100.832% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 64.411% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 134.544% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 18.454% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 4953.153% |
| Radius Health, Inc. | 359.28 Million USD | 101.443% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 2729.713% |
| ProPhase Labs, Inc. | 19.23 Million USD | 126.967% |
| Phibro Animal Health Corporation | 454.84 Million USD | 101.14% |
| Procaps Group S.A. | 242.93 Million USD | 102.135% |
| Alvotech | 1.06 Billion USD | 100.487% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 241.001% |
| Viatris Inc. | 17.13 Billion USD | 100.03% |
| Rockwell Medical, Inc. | 4.45 Million USD | 216.383% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -6.336% |
| SIGA Technologies, Inc. | -148.68 Million USD | 96.512% |
| Tilray Brands, Inc. | 158.97 Million USD | 103.262% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 104.254% |
| Shineco, Inc. | 29.29 Million USD | 117.706% |
| PetIQ, Inc. | 351.93 Million USD | 101.474% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -78.741% |
| Incannex Healthcare Limited | -5.48 Million USD | 5.451% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 102.925% |
| Alimera Sciences, Inc. | 55.3 Million USD | 109.376% |
| Silver Spike Investment Corp. | -32.61 Million USD | 84.098% |
| Assertio Holdings, Inc. | -32.52 Million USD | 84.057% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -248.355% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -2.483% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -7.728% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 36.859% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 222.979% |
| Hempacco Co., Inc. | 13.61 Million USD | 138.091% |
| Talphera, Inc. | -5.72 Million USD | 9.351% |
| Alvotech | 1.06 Billion USD | 100.487% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 172.583% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 94.638% |
| Currenc Group, Inc. | -16.57 Million USD | 68.708% |
| Kamada Ltd. | -46.43 Million USD | 88.831% |
| Indivior PLC | -33.95 Million USD | 84.725% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 2090.233% |
| Flora Growth Corp. | -713 Thousand USD | -627.354% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 36.859% |
| Evolus, Inc. | 63.7 Million USD | 108.14% |
| HUTCHMED (China) Limited | -197.45 Million USD | 97.374% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 101.082% |
| Akanda Corp. | 3.9 Million USD | 232.808% |